NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.
Flawless balance sheet with limited growth.
Share Price & News
How has NewLink Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: NLNK underperformed the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: NLNK underperformed the US Market which returned 7.3% over the past year.
Price Volatility Vs. Market
How volatile is NewLink Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StDid You Manage To Avoid NewLink Genetics's (NASDAQ:NLNK) Devastating 93% Share Price Drop?
1 month ago | Simply Wall StWhat Kind Of Share Price Volatility Should You Expect For NewLink Genetics Corporation (NASDAQ:NLNK)?
2 months ago | Simply Wall StShould You Worry About NewLink Genetics Corporation's (NASDAQ:NLNK) CEO Pay?
Is NewLink Genetics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate NLNK's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate NLNK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NLNK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NLNK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate NLNK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NLNK is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2.6x).
How is NewLink Genetics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NLNK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NLNK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NLNK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NLNK's revenue (21.7% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: NLNK's revenue (21.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if NLNK's Return on Equity is forecast to be high in 3 years time
How has NewLink Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: NLNK is unprofitable, and losses have increased over the past 5 years at a rate of -33% per year.
Accelerating Growth: Unable to compare NLNK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NLNK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).
Return on Equity
High ROE: NLNK has a negative Return on Equity (-38.65%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: NLNK is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: NLNK is currently unprofitable, so its Return on Capital Employed is negative.
How is NewLink Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: NLNK's short term assets ($110.2M) exceeds its short term liabilities ($8.6M)
Long Term Liabilities: NLNK's short term assets (110.2M) exceeds its long term liabilities (13.5M)
Debt to Equity History and Analysis
Debt Level: NLNK's debt to equity ratio (0.07%) is considered satisfactory
Reducing Debt: NLNK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Inventory Level: NLNK has a low level of unsold assets or inventory.
Debt Coverage by Assets: NLNK's debt is covered by short term assets (assets are 1489.162160x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NLNK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NLNK has sufficient cash runway for 2.526098 years if free cash flow continues to grow at historical rates of 19.7% each year.
What is NewLink Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate NLNK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NLNK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if NLNK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NLNK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NLNK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of NewLink Genetics's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
NewLink Genetics has no CEO, or we have no data on them.
Management Age and Tenure
Experienced Management: NLNK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
Experienced Board: NLNK's board of directors are considered experienced (4.3 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Mario Mautino (53yo)
Senior VP of Drug Discovery & Intellectual Property Officer
- Tenure: 0yrs
Carl Langren (64yo)
CFO & Principal Accounting Officer
- Tenure: 1.3yrs
- Compensation: US$842.81k
Gene Kennedy (50yo)
Chief Medical Officer
- Tenure: 1.9yrs
- Compensation: US$1.21m
Director of Investor Relations
- Tenure: 0yrs
VP of Finance & Controller
- Tenure: 1.3yrs
- Tenure: 1.3yrs
Lota Zoth (59yo)
- Tenure: 6.9yrs
- Compensation: US$181.13k
Tom Raffin (72yo)
Lead Independent Director
- Tenure: 0yrs
- Compensation: US$204.26k
Matt Sherman (63yo)
- Tenure: 1.4yrs
- Compensation: US$358.92k
Ernest Talarico (48yo)
- Tenure: 20.8yrs
- Compensation: US$175.00k
Chad Johnson (40yo)
- Tenure: 1.6yrs
- Compensation: US$393.32k
NewLink Genetics Corporation's company bio, employee growth, exchange listings and data sources
- Name: NewLink Genetics Corporation
- Ticker: NLNK
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$47.387m
- Shares outstanding: 37.31m
- Website: https://www.newlinkgenetics.com
Number of Employees
- NewLink Genetics Corporation
- 2503 South Loop Drive
- Suite 5100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NLNK||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2011|
|4NX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2011|
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developi ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/18 00:18|
|End of Day Share Price||2019/10/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.